Auteurs

Dr. Manja Epping

Associé

Read More

Evelyne Friedel

Associé

Read More

Matthew Royle, Ph.D.

Associé

Read More
Auteurs

Dr. Manja Epping

Associé

Read More

Evelyne Friedel

Associé

Read More

Matthew Royle, Ph.D.

Associé

Read More

1 janvier 0001 | 48:40

Biosimilars - an overview of the route to market in the US and Europe

Many of the top selling drugs worldwide are biologics and many companies are seeking to produce biosimilars to compete in these lucrative markets. Activity relating to biosimilars is intensifying in the US following the introduction of the BPCIA and continues in Europe since the first biosimilars were authorised in 2006. Successfully bringing a biosimilar to market raises different challenges to small molecule generics and there are differences in the approach in the US and Europe.

Taylor Wessing and Willkie Farr & Gallagher are hosting a series of three webinars covering various aspects of market access for biosimilars.

In this first webinar 'Biosimilars - an overview of the route to market in the US and Europe' we discussed:

  • Basics of the regulatory system in the US and Europe
  • History of approvals and launches in the US and Europe
  • Overview of the "patent dance" under the BPCIA and contrast to the position in Europe
Call To Action Arrow Image

Latest insights in your inbox

Subscribe to newsletters on topics relevant to you.

Subscribe
Subscribe

Related Insights

Sciences de la vie et Santé

Biologics and biosimilars litigation update

25 novembre 2020
Quick read

par plusieurs auteurs

Cliquer ici pour en savoir plus
centrifuge-machine
Sciences de la vie et Santé

Dissecting the Regeneron v Kymab mouse case – what it says and its impact on patents

27 juillet 2020
QUICK READ

par plusieurs auteurs

Cliquer ici pour en savoir plus
woman-with-scientific-model
Sciences de la vie et Santé

Everything biologic and biosimilar in-house counsel need to know about COVID-19

29 avril 2020

par plusieurs auteurs

Cliquer ici pour en savoir plus

Événements connexes